Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

LGND

Ligand Pharmaceuticals, Inc

Feb 17 • 04:00PM ET

187.51

+3.68 2.00 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN BIIB GILD INCY AMGN BMY PFE MRNA RDY

| Held by: IJR VTI IWM VB VBR VXF SPSM IJT IWN VTWO

Index	RUT	P/E	90.25	EPS (ttm)	2.08	Insider Own	2.41%	Shs Outstand	19.66M	Perf Week	0.31%
Market Cap	3.69B	Forward P/E	22.28	EPS next Y	8.42	Insider Trans	-5.07%	Shs Float	19.21M	Perf Month	-4.37%
Enterprise Value	3.48B	PEG	1.19	EPS next Q	1.50	Inst Own	105.82%	Short Float	6.68%	Perf Quarter	-6.84%
Income	48.58M	P/S	14.69	EPS this Y	32.06%	Inst Trans	4.36%	Short Ratio	5.83	Perf Half Y	24.11%
Sales	251.23M	P/B	3.88	EPS next Y	11.03%	ROA	4.00%	Short Interest	1.28M	Perf YTD	-0.83%
Book/sh	48.34	P/C	5.55	EPS next 5Y	18.69%	ROE	5.42%	52W High	212.49 -11.76%	Perf Year	56.26%
Cash/sh	33.76	P/FCF	120.45	EPS past 3/5Y	- -	ROIC	3.47%	52W Low	93.58 100.37%	Perf 3Y	154.53%
Dividend Est.	-	EV/EBITDA	53.42	Sales past 3/5Y	-11.55% 6.80%	Gross Margin	81.19%	Volatility	3.91% 3.95%	Perf 5Y	95.25%
Dividend TTM	-	EV/Sales	13.84	EPS Y/Y TTM	-9.12%	Oper. Margin	11.48%	ATR (14)	7.83	Perf 10Y	221.59%
Dividend Ex-Date	Jul 02, 2010	Quick Ratio	24.30	Sales Y/Y TTM	64.83%	Profit Margin	19.34%	RSI (14)	44.42	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	24.69	EPS Q/Q	1559.91%	SMA20	-2.90%	Beta	1.22	Target Price	243.44
Payout	-	Debt/Eq	0.47	Sales Q/Q	122.85%	SMA50	-3.05%	Rel Volume	0.56	Prev Close	183.83
Employees	68	LT Debt/Eq	0.47	Earnings	Feb 26 BMO	SMA200	16.26%	Avg Volume	219.96K	Price	187.51
IPO	Nov 18, 1992	Option/Short	Yes / Yes	EPS/Sales Surpr.	60.24% 96.55%	Trades		Volume	123,433	Change	2.00%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-25	Initiated	Citigroup	Buy	$270
Apr-10-25	Initiated	Stifel	Buy	$143
Oct-03-24	Initiated	Oppenheimer	Outperform	$135
Jul-30-24	Initiated	RBC Capital Mkts	Outperform	$130
Apr-14-21	Resumed	Stephens	Overweight	$200
Feb-04-21	Reiterated	H.C. Wainwright	Buy	$229 → $310
Oct-06-20	Initiated	Barclays	Overweight	$156
Mar-24-20	Downgrade	Argus	Buy → Hold
Mar-10-20	Initiated	Guggenheim	Neutral
Feb-06-20	Initiated	The Benchmark Company	Buy	$135
Sep-19-19	Upgrade	Barclays	Equal Weight → Overweight	$110 → $132
Jun-11-19	Initiated	Barclays	Equal Weight	$131
May-03-19	Reiterated	H.C. Wainwright	Buy	$254 → $214
Mar-06-19	Reiterated	H.C. Wainwright	Buy	$281 → $254
Oct-29-18	Upgrade	ROTH Capital	Neutral → Buy
Oct-02-18	Reiterated	H.C. Wainwright	Buy	$270 → $280
Sep-11-18	Reiterated	Argus	Buy	$260 → $300
Aug-17-18	Initiated	Goldman	Neutral	$256
Aug-08-18	Downgrade	ROTH Capital	Buy → Neutral
Jun-21-18	Initiated	Argus	Buy	$260

Show Previous Ratings

Feb-12-26 07:00AM	Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 (GlobeNewswire)
Feb-04-26 07:00AM	Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-30-26 12:39PM	This Pharma Stock Eyes Entries, Battles For Key Level Amid 68% Earnings Growth (Investor's Business Daily)
Jan-13-26 04:36PM	Travere, Ligand Hammered On A Surprise Delay For Their Linchpin Drug (Investor's Business Daily) -8.72%
Jan-12-26 10:32AM	Gamble on Huge Gains with These 3 Best Biotech Stocks to Buy for 2026 (Barchart)
07:13AM	Loading…
Jan-08-26 07:13AM	Dow Jones Futures Fall; Lockheed, Defense Giants Bounce On $1.5 Trillion Trump 'Dream Military' (Investor's Business Daily)
Jan-07-26 05:05PM	Dow Jones Futures: Stock Market Fades From Highs; Eli Lilly, Google Lead New Buys (Investor's Business Daily)
Dec-09-25 07:00AM	Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance (GlobeNewswire)
Nov-20-25 01:34PM	Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 92% This Year (Investor's Business Daily)
Nov-19-25 08:11AM	What Makes Ligand Pharmaceuticals (LGND) an Investment Choice? (Insider Monkey)
Nov-18-25 08:03AM	Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year (Investor's Business Daily)
Nov-10-25 05:31AM	Pelthos acquires US rights to Xepi cream from Biofrontera and Ferrer (Pharmaceutical Technology)
Nov-06-25 07:14AM	Ligand: Q3 Earnings Snapshot (Associated Press Finance) +9.37%
07:00AM	Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance (GlobeNewswire)
Oct-30-25 04:01PM	Ligand to Participate in November Investor Conferences (GlobeNewswire)
07:00AM	Loading…
Oct-23-25 07:00AM	Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
Oct-16-25 07:00AM	Ligand to Host Investor Day on December 9, 2025 (GlobeNewswire)
Oct-09-25 07:00AM	Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients (GlobeNewswire)
Aug-19-25 04:00PM	Ligand to Participate in September Investor Conferences (GlobeNewswire)
Aug-14-25 04:00PM	Ligand Announces Closing of Convertible Senior Notes Offering (GlobeNewswire)
Aug-12-25 08:14AM	Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
Aug-11-25 11:46PM	Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering (GlobeNewswire)
07:00AM	Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 (GlobeNewswire)
Aug-07-25 07:24AM	Ligand: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance (GlobeNewswire)
Aug-05-25 07:00AM	Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings (GlobeNewswire)
Jul-31-25 04:01PM	Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed (GlobeNewswire)
Jul-24-25 07:00AM	Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire)
Jul-17-25 02:10PM	Ligand Pharmaceuticals Stock Earns 84 RS Rating (Investor's Business Daily) +6.13%
Jul-12-25 02:00PM	Top 3 small-cap stock picks while navigating trade uncertainty (Yahoo Finance Video)
10:43AM	Loading…
Jul-10-25 10:43AM	LGND Raises $9M to Make Earth Data Intuitive and Actionable (PR Newswire)
09:58AM	LGND wants to make ChatGPT for the Earth (TechCrunch)
08:00AM	Ligand Partner Pelthos Therapeutics Launches ZELSUVMI (GlobeNewswire)
Jul-03-25 07:17AM	Ligands LNHC concludes merger with CHRO (Pharmaceutical Technology)
Jul-02-25 07:00AM	Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement (GlobeNewswire)
07:00AM	Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics (GlobeNewswire)
Jun-11-25 07:00AM	Ligand Announces 2025 Investor Day in New York City (GlobeNewswire)
May-14-25 07:00AM	Ligand to Ring the Nasdaq Opening Bell on May 19, 2025 (GlobeNewswire)
May-08-25 07:44AM	Ligand Pharmaceuticals Reiterates FY25 Outlook - Update (RTT News)
07:00AM	Ligand Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
12:09PM	Ligand Pharmaceuticals Q1 2025 Earnings Preview (Seeking Alpha)
May-01-25 07:00AM	Ligand to Participate in May Investor Conferences (GlobeNewswire)
Apr-24-25 07:00AM	Ligand to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Apr-20-25 09:35AM	Revisiting Ligand Pharmaceuticals, Ready To Accumulate If Shares Dip Below $100 (Seeking Alpha)
Apr-17-25 06:00AM	Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics (GlobeNewswire)
Apr-03-25 11:50AM	Bumbershoot Holdings 2024 Investor Letter (Seeking Alpha) -5.17%
Mar-31-25 04:03PM	Impax Small Cap Fund Q4 2024 Commentary (Seeking Alpha)
07:30AM	Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-03-25 07:00AM	Ligand to Participate in March Investor Conferences (GlobeNewswire) -8.22%
Feb-27-25 07:00AM	Ligand Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-25-25 07:00AM	Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences (GlobeNewswire)
Feb-13-25 07:00AM	Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 (Business Wire)
Feb-06-25 07:00AM	Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Dec-12-24 07:45AM	Ligand price target raised to $151 from $135 at Oppenheimer (TipRanks) -5.69%
Dec-10-24 09:00AM	Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance (Business Wire)
Nov-14-24 08:00AM	Ligand to Present at Stifel 2024 Healthcare Conference (Business Wire) -5.43%
Nov-07-24 07:00AM	Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance (Business Wire) +11.12%
Nov-01-24 08:01AM	Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston (Business Wire)
Oct-23-24 04:01PM	Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024 (Business Wire)
Oct-17-24 07:30AM	Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer (GlobeNewswire)
Sep-06-24 09:20AM	Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy (Business Wire)
Aug-20-24 09:00AM	Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-06-24 04:01PM	Ligand Reports Second Quarter 2024 Financial Results (Business Wire) -5.78%
Jul-24-24 06:30AM	Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement (ACCESSWIRE)
Jul-23-24 04:01PM	Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024 (Business Wire)
Jul-08-24 07:00AM	Ligand to Acquire APEIRON Biologics AG for $100 Million (Business Wire)
Jul-01-24 08:00AM	Lifecore Biomedical Announces Cooperation Agreement with 22NW (GlobeNewswire)
Jun-27-24 08:00AM	Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years (Business Wire) +5.80%
Jun-18-24 08:00AM	Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for Adults (Business Wire)
Jun-14-24 12:00PM	What Makes Ligand (LGND) a New Strong Buy Stock (Zacks)
Jun-06-24 11:31AM	Why Is Ligand (LGND) Up 4% Since Last Earnings Report? (Zacks)
Jun-04-24 09:55AM	Does Ligand (LGND) Have the Potential to Rally 32.33% as Wall Street Analysts Expect? (Zacks) -8.05%
08:50AM	Recent Price Trend in Ligand (LGND) is Your Friend, Here's Why (Zacks)
May-23-24 04:59PM	Ligand to Participate in Upcoming Investor Conferences (Business Wire)
May-20-24 06:00AM	3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off (InvestorPlace)
May-13-24 12:00PM	Ligand (LGND) Moves to Strong Buy: Rationale Behind the Upgrade (Zacks)
May-10-24 08:50AM	Ligand (LGND) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
May-09-24 09:40AM	Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year? (Zacks) +7.17%
May-08-24 01:22PM	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript (Insider Monkey) +9.75%
12:19PM	Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates (Zacks)
May-07-24 09:01PM	LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:40PM	Ligand Pharmaceuticals (LGND) Tops Q1 Earnings Estimates (Zacks)
04:00PM	Ligand Reports First Quarter 2024 Financial Results (Business Wire)
11:29AM	Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:30AM	Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement (Business Wire)
Apr-23-24 08:31AM	Ligand to Report First Quarter 2024 Financial Results on May 7, 2024 (Business Wire)
Apr-17-24 09:55AM	Wall Street Analysts Predict a 45.56% Upside in Ligand (LGND): Here's What You Should Know (Zacks)
Apr-08-24 08:15AM	Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference (Business Wire)
Apr-05-24 06:00PM	Ligand Pharmaceuticals (LGND) Stock Dips While Market Gains: Key Facts (Zacks)
Apr-04-24 09:30AM	Wall Street Analysts Think Ligand (LGND) Is a Good Investment: Is It? (Zacks)
09:00AM	Investors Heavily Search Ligand Pharmaceuticals Incorporated (LGND): Here is What You Need to Know (Zacks)
Apr-03-24 09:00AM	Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI (Business Wire)
Apr-01-24 06:15PM	Ligand Pharmaceuticals (LGND) Ascends While Market Falls: Some Facts to Note (Zacks)
Mar-28-24 11:30AM	Ligand (LGND) Down 15.5% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-26-24 06:15PM	Ligand Pharmaceuticals (LGND) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Mar-21-24 09:00AM	Here is What to Know Beyond Why Ligand Pharmaceuticals Incorporated (LGND) is a Trending Stock (Zacks)
Mar-20-24 06:00PM	Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider (Zacks)
Mar-19-24 09:30AM	Ligand (LGND) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
Mar-14-24 06:00PM	Ligand Pharmaceuticals (LGND) Declines More Than Market: Some Information for Investors (Zacks)

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that involves clinical development and commercialization of high-value medicines. Its platforms, Captisol and NITRICI, offer technology with broad applicability in drug development to a large network of biopharmaceutical partners, including the largest pharmaceutical manufacturers in the world. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KOZARICH JOHN W	Director	Feb 02 '26	Sale	195.91	467	91,490	43,187	Feb 04 05:18 PM
KOZARICH JOHN W	Director	Feb 02 '26	Proposed Sale	192.18	467	89,748		Feb 02 04:12 PM
KOZARICH JOHN W	Director	Jan 02 '26	Sale	189.58	467	88,532	43,654	Jan 06 07:47 PM
KOZARICH JOHN W	Director	Jan 02 '26	Proposed Sale	188.60	467	88,076		Jan 02 04:04 PM
Espinoza Octavio	Chief Financial Officer	Dec 16 '25	Option Exercise	69.00	2,381	164,298	28,567	Dec 18 04:19 PM
Espinoza Octavio	Chief Financial Officer	Dec 12 '25	Sale	188.31	1,804	339,711	26,186	Dec 16 06:36 PM
OCTAVIO ESPINOZA	Officer	Dec 12 '25	Proposed Sale	188.31	1,804	339,711		Dec 12 05:22 PM
Aryeh Jason	Director	Dec 08 '25	Option Exercise	69.51	2,034	141,383	71,323	Dec 08 07:38 PM
KOZARICH JOHN W	Director	Dec 01 '25	Sale	195.84	467	91,457	44,121	Dec 03 05:08 PM
KOZARICH JOHN W	Director	Dec 01 '25	Proposed Sale	199.88	467	93,344		Dec 01 04:08 PM
Gray Nancy Ryan	Director	Nov 07 '25	Option Exercise	69.58	6,571	457,185	11,650	Nov 12 04:45 PM
Gray Nancy Ryan	Director	Nov 07 '25	Sale	205.45	6,571	1,350,012	8,094	Nov 12 04:45 PM
LAMATTINA JOHN L	Director	Nov 07 '25	Option Exercise	67.78	4,179	283,232	32,869	Nov 12 04:44 PM
LAMATTINA JOHN L	Director	Nov 07 '25	Sale	205.45	4,179	858,576	30,724	Nov 12 04:44 PM
NANCY GRAY	Director	Nov 07 '25	Proposed Sale	205.45	6,571	1,350,012		Nov 07 05:05 PM
JOHN L LAMATTINA	Director	Nov 07 '25	Proposed Sale	205.45	4,179	858,576		Nov 07 04:05 PM
KOZARICH JOHN W	Director	Nov 03 '25	Sale	191.05	467	89,219	44,588	Nov 05 05:22 PM
KOZARICH JOHN W	Director	Nov 03 '25	Proposed Sale	191.05	467	89,219		Nov 03 04:05 PM
KOZARICH JOHN W	Director	Oct 01 '25	Sale	179.44	467	83,800	45,055	Oct 03 04:45 PM
KOZARICH JOHN W	Director	Oct 01 '25	Proposed Sale	176.68	467	82,510		Oct 01 04:09 PM
Aryeh Jason	Director	Sep 23 '25	Sale	170.81	10,000	1,708,088	69,289	Sep 24 05:11 PM
JASON M ARYEH	Director	Sep 23 '25	Proposed Sale	170.81	10,000	1,708,087		Sep 23 04:50 PM
Aryeh Jason	Director	Sep 17 '25	Proposed Sale	168.50	10,000	1,685,000		Sep 17 12:41 PM
KOZARICH JOHN W	Director	Sep 02 '25	Sale	162.26	467	75,775	45,522	Sep 04 05:47 PM
KOZARICH JOHN W	Director	Sep 02 '25	Proposed Sale	161.71	467	75,518		Sep 02 04:16 PM
KOZARICH JOHN W	Director	Aug 01 '25	Sale	131.88	467	61,586	45,989	Aug 05 05:03 PM
KOZARICH JOHN W	Director	Aug 01 '25	Proposed Sale	131.00	467	61,177		Aug 01 04:04 PM
KOZARICH JOHN W	Director	Jul 10 '25	Sale	125.00	934	116,750	46,456	Jul 11 06:17 PM
KOZARICH JOHN W	Officer	Jul 10 '25	Proposed Sale	125.00	934	116,750		Jul 10 05:08 PM
Reardon Andrew	CLO & Secretary	Jun 23 '25	Sale	114.08	500	57,042	31,903	Jun 24 08:29 PM
ANDREW THOMAS REARDON	Officer	Jun 23 '25	Proposed Sale	114.08	500	57,042		Jun 23 05:07 PM
Reardon Andrew	CLO & Secretary	Jun 10 '25	Sale	114.54	500	57,271	32,403	Jun 12 05:51 PM
ANDREW THOMAS REARDON	Officer	Jun 10 '25	Proposed Sale	114.54	500	57,271		Jun 10 06:49 PM
Reardon Andrew	CLO & Secretary	May 15 '25	Sale	104.00	1,000	104,000	32,903	Jun 02 08:06 PM
ANDREW THOMAS REARDON	Officer	May 15 '25	Proposed Sale	104.00	1,000	104,000		May 15 05:14 PM
Davis Todd C	Chief Executive Officer	May 09 '25	Buy	105.20	9,510	1,000,456	161,234	May 13 08:05 PM
Espinoza Octavio	Chief Financial Officer	May 09 '25	Buy	104.06	1,500	156,090	27,932	May 13 08:04 PM
Sabba Stephen L	Director	Apr 01 '25	Option Exercise	52.30	2,406	125,834	32,584	Apr 16 09:34 AM
Sabba Stephen L	Director	Mar 18 '25	Proposed Sale	106.00	2,406	255,036		Mar 18 04:01 PM
Espinoza Octavio	Chief Financial Officer	Mar 04 '25	Sale	115.03	5,000	575,148	18,879	Mar 06 06:55 PM
Espinoza Octavio	Officer	Mar 04 '25	Proposed Sale	115.03	5,000	575,149		Mar 04 05:10 PM

Open in Screener

NXPI

NXP Semiconductors NV

Feb 17 • 04:00PM ET

245.09

+0.66 0.27 %

Technology • Semiconductors • Netherlands • NASD

NXPI NXP Semiconductors NV daily Stock Chart

Peers: TXN INTC ON ADI QCOM NVDA AVGO MCHP MRVL AMD

| Held by: VOO QQQ SOXX IVV SPY SMH XLK VGT SOXL MOAT

Index	NDX, S&P 500	P/E	30.84	EPS (ttm)	7.95	Insider Own	0.12%	Shs Outstand	251.67M	Perf Week	7.07%
Market Cap	61.68B	Forward P/E	14.65	EPS next Y	16.73	Insider Trans	-9.63%	Shs Float	251.37M	Perf Month	2.72%
Enterprise Value	71.03B	PEG	0.79	EPS next Q	2.98	Inst Own	95.36%	Short Float	3.28%	Perf Quarter	21.80%
Income	2.02B	P/S	5.03	EPS this Y	17.97%	Inst Trans	-1.82%	Short Ratio	2.66	Perf Half Y	7.13%
Sales	12.27B	P/B	6.15	EPS next Y	20.08%	ROA	7.93%	Short Interest	8.24M	Perf YTD	12.91%
Book/sh	39.84	P/C	18.88	EPS next 5Y	18.60%	ROE	21.01%	52W High	256.36 -4.40%	Perf Year	9.35%
Cash/sh	12.98	P/FCF	24.68	EPS past 3/5Y	-9.08% 112.19%	ROIC	9.61%	52W Low	148.09 65.50%	Perf 3Y	30.05%
Dividend Est.	4.48 (1.83%)	EV/EBITDA	17.92	Sales past 3/5Y	-2.42% 7.33%	Gross Margin	53.37%	Volatility	4.76% 3.91%	Perf 5Y	29.21%
Dividend TTM	4.06 (1.65%)	EV/Sales	5.79	EPS Y/Y TTM	-18.67%	Oper. Margin	25.53%	ATR (14)	9.68	Perf 10Y	248.39%
Dividend Ex-Date	Dec 10, 2025	Quick Ratio	1.38	Sales Y/Y TTM	-2.74%	Profit Margin	16.47%	RSI (14)	58.74	Recom	1.50
Dividend Gr. 3/5Y	6.30% 22.04%	Current Ratio	2.05	EPS Q/Q	-7.16%	SMA20	5.06%	Beta	1.43	Target Price	261.44
Payout	50.72%	Debt/Eq	1.22	Sales Q/Q	7.20%	SMA50	5.96%	Rel Volume	0.56	Prev Close	244.43
Employees	33100	LT Debt/Eq	1.09	Earnings	Feb 02 AMC	SMA200	11.96%	Avg Volume	3.09M	Price	245.09
IPO	Aug 06, 2010	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.15% 0.82%	Trades		Volume	1,727,330	Change	0.27%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-25	Initiated	Goldman	Buy	$276
Apr-30-25	Reiterated	TD Cowen	Buy	$185 → $210
Feb-20-25	Upgrade	Citigroup	Neutral → Buy	$210 → $290
Feb-12-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$231 → $257
Feb-05-25	Upgrade	Citigroup	Sell → Neutral	$200 → $210
Jan-10-25	Upgrade	Goldman	Neutral → Buy	$260 → $257
Nov-22-24	Initiated	Wells Fargo	Overweight	$250
Nov-12-24	Initiated	Loop Capital	Buy	$300
Nov-08-24	Reiterated	TD Cowen	Buy	$300 → $285
Oct-07-24	Upgrade	UBS	Neutral → Buy	$275 → $285
Jul-24-24	Reiterated	TD Cowen	Buy	$330 → $310
May-24-24	Upgrade	Mizuho	Neutral → Buy	$265 → $325
May-13-24	Initiated	Jefferies	Buy	$255 → $325
Apr-16-24	Initiated	Evercore ISI	Outperform	$300
Mar-12-24	Reiterated	TD Cowen	Outperform	$270 → $300
Feb-07-24	Reiterated	TD Cowen	Outperform	$250 → $270
Jan-23-24	Initiated	Cantor Fitzgerald	Overweight	$260
Jan-18-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$255
Jan-16-24	Upgrade	Barclays	Equal Weight → Overweight	$200 → $260
Dec-05-23	Reiterated	TD Cowen	Outperform	$240 → $250

Show Previous Ratings

Feb-16-26 10:09AM	Analog Devices to Report Q1 Earnings: What's in Store for the Stock? (Zacks)
Feb-13-26 11:39AM	75% of Breaches Start With Stolen Credentials. Enterprises Are Retooling. (PR Newswire)
Feb-12-26 10:07AM	Stocks Mixed on Strength in Chipmakers and Weakness in Cisco Systems (Barchart)
Feb-11-26 07:15PM	Analyst Report: NXP Semiconductors N.V. (Morningstar Research) +5.55%
11:23AM	Stocks Turn Mixed as Software Stocks Slide (Barchart)
11:36PM	Loading…
Feb-09-26 11:36PM	1 Semiconductor Stock to Research Further and 2 We Find Risky (StockStory)
04:34PM	Stocks Settle Higher on Strength in Tech (Barchart)
03:08AM	What Are Wall Street Analysts' Target Price for NXP Semiconductors Stock? (Barchart)
12:31AM	5 Insightful Analyst Questions From NXP Semiconductors's Q4 Earnings Call (StockStory)
Feb-06-26 08:50AM	Multi-Billion-Dollar VRU Detection Market Unlocking New Growth Opportunities (PR Newswire)
Feb-04-26 11:38AM	Why NXP Semiconductors' Post-Earnings Dip Could Be a Buying Window (MarketBeat)
05:07AM	NXP CEO says demand for 'physical AI' boosting outlook (Reuters)
Feb-03-26 06:03PM	Stocks to Watch Tuesday Recap: PayPal, PepsiCo, AMD, Disney (The Wall Street Journal)
04:26PM	Stocks Tumble on AI Disruption Fears (Barchart)
03:40PM	Analyst Report: NXP Semiconductors N.V. (Morningstar Research)
02:02PM	Loading…
02:02PM	NXP Semiconductors NV (NXPI) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
12:38PM	NXP Semiconductors Q4 Earnings Call Highlights (MarketBeat)
12:26PM	NXPI Q4 Deep Dive: Automotive and Industrial Growth Offset by Portfolio Shifts and Market Skepticism (StockStory)
11:50AM	Why NXP Semiconductors (NXPI) Shares Are Getting Obliterated Today (StockStory)
11:14AM	Software Stocks Retreat and Drag the Broader Market Lower (Barchart)
10:18AM	Will Qualcomm's Next-Generation Snapdragon Elite Chip Fuel Its Shares? (Zacks)
09:59AM	Nasdaq Slips, Gold and Silver Stage Substantial Recovery (Barchart)
09:40AM	Stocks to Watch Tuesday: PayPal, PepsiCo, AMD, Disney (The Wall Street Journal)
08:23AM	NXP Semiconductors' Q4 Earnings and Revenues Beat Estimates (Zacks)
05:54AM	Teradyne's 'blowout' guidance sees stock surge, and other early movers (MarketWatch)
05:25AM	These Stocks Are Todays Movers: Palantir, Teradyne, Tesla, AMD, NXP Semiconductors, and More (Barrons.com)
03:39AM	Stocks to Watch Tuesday: Palantir, Teradyne, AMD (The Wall Street Journal)
Feb-02-26 08:32PM	Palantir, Teradyne, Caterpillar, NXP Semiconductors And Disney: Why These 5 Stocks Are On Investors' Radars Today (Benzinga)
06:00PM	NXP (NXPI) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:46PM	Market Indexes Bounce Back to Start a New Trading Week (Zacks)
05:44PM	Loading…
05:44PM	NXP Semiconductors forecasts upbeat quarter, signaling industrial market bottom (Reuters)
05:20PM	NXP Semiconductors (NXPI) Q4 Earnings and Revenues Surpass Estimates (Zacks)
05:06PM	Tyson Foods, Disney, NXP Semiconductors: Earnings movers (Yahoo Finance Video)
04:39PM	NXP Semiconductors Logs Higher Sales Amid Improving Demand (The Wall Street Journal)
04:31PM	Stocks to Watch Monday Recap: Coinbase, Newmont, Disney (The Wall Street Journal)
04:30PM	NXP: Q4 Earnings Snapshot (Associated Press Finance)
04:28PM	NXP Semiconductors Stock Slips After Q4 Earnings Release (Benzinga)
04:26PM	NXP Semiconductors's (NASDAQ:NXPI) Q4 Sales Top Estimates, Inventory Levels Improve (StockStory)
04:10PM	NXP Semiconductors Reports Fourth Quarter and Full-Year 2025 Results (GlobeNewswire)
11:53AM	What You Need to Know Before NXP Semiconductors Q4 2025 Earnings (24/7 Wall St.)
11:19AM	Stocks Gain on US Manufacturing Strength (Barchart)
11:12AM	Market Awaits January Manufacturing Numbers (Zacks)
10:35AM	Six More Weeks of Q4 Earnings Season? (Zacks)
09:38AM	Stocks to Watch Monday: Coinbase, Newmont, Disney (The Wall Street Journal)
08:29AM	Palantir, AMD, Amazon and More Stocks with Earnings This Week (Benzinga)
06:56AM	Palantir Earnings Arrive Just as Stock Could Use Some Good News (Bloomberg)
05:27AM	Stock Market Today: S&P 500, Dow Futures Decline Amid Kevin Warsh's Fed Chair Nomination-Walt Disney, Strategy, GameStop In Focus (Benzinga)
02:13AM	Jobs Report, Big Tech and Pharma Earnings: What to Watch This Week (The Wall Street Journal)
Feb-01-26 07:47AM	January jobs data, Alphabet and Amazon earnings, more Warsh fallout: What to watch this week (Yahoo Finance)
Jan-31-26 10:04PM	NXP Semiconductors (NXPI) Q4 Earnings Report Preview: What To Look For (StockStory)
Jan-30-26 04:57PM	Jobs Report, More Tech Earnings: What to Watch Next Week (The Wall Street Journal)
11:16AM	Stocks Slip as Bond Yields Rise after Warsh Picked for Fed Chair (Barchart)
10:00AM	Stocks Fall as Trump Nominates Warsh for Fed Chair (Barchart)
08:44AM	FLEX Set to Report Q3 Earnings: Here's What You Should Know (Zacks)
08:41AM	Lumen to Report Q4 Earnings: Here's What Investors Should Know (Zacks)
Jan-29-26 06:15PM	Why NXP Semiconductors (NXPI) Dipped More Than Broader Market Today (Zacks)
10:00AM	Microchip Technology (MCHP) Earnings Expected to Grow: Should You Buy? (Zacks)
09:35AM	NXP Semiconductors (NXPI) Just Overtook the 20-Day Moving Average (Zacks)
09:32AM	NXPI Likely to Beat Q4 Earnings Estimates: How to Play the Stock (Zacks)
08:55AM	Why Investors Need to Take Advantage of These 2 Computer and Technology Stocks Now (Zacks)
08:12AM	Woodward to Report Q1 Earnings: Here's What Investors Should Know (Zacks)
Jan-28-26 04:32PM	Stocks Finish Mixed as Fed Keeps Interest Rates Steady (Barchart)
11:15AM	Stocks Mixed After the Fed Pauses Rate Cuts (Barchart)
09:15AM	Ahead of NXP (NXPI) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics (Zacks)
07:23AM	Jim Cramer Calls NXP Semiconductors "Cyclical" (Insider Monkey)
Jan-26-26 10:00AM	NXP Semiconductors (NXPI) Earnings Expected to Grow: Should You Buy? (Zacks)
Jan-24-26 11:00AM	Citi Analysts Love This 1 Lesser-Known Chip Stock Ahead of Earnings (Barchart)
Jan-23-26 04:34PM	Stocks Finish Mostly Higher Despite a Plunge in Intel (Barchart)
Jan-22-26 11:36PM	1 Profitable Stock with Exciting Potential and 2 We Avoid (StockStory)
Jan-21-26 06:18PM	TD Cowen Names NXP (NXPI) a Top Pick, Raises Price Target to $285 (Insider Monkey)
02:17PM	US Semiconductor Supply, Demand Realign For 2026, Says BofA Analyst: What Are The Top Stock Picks? (Benzinga)
06:19AM	Nvidia and Broadcom Look Attractive Again. Citi Names Top Chip Picks (GuruFocus.com)
Jan-19-26 11:04PM	2 Reasons to Avoid NXPI and 1 Stock to Buy Instead (StockStory)
10:17AM	ADI's Consumer Revenues Rise 19% Y/Y in FY25: More Growth Ahead? (Zacks)
Jan-16-26 07:47AM	NXP Semiconductors price target raised to $285 from $275 at Citi (TipRanks)
Jan-15-26 08:00AM	NXP Semiconductors Announces Conference Call to Review its Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Jan-13-26 09:00AM	Origin AI and NXP Team Up to Accelerate Embedded WiFi Sensing for the Smart Home (PR Newswire)
Jan-11-26 11:01AM	Consumer Tech News (Jan 5-9): Semiconductors Steal CES 2026 Spotlight, AI Regulation Tightens As Governments Crack Down & More (Benzinga)
Jan-09-26 06:15PM	NXP Semiconductors (NXPI) Rises Higher Than Market: Key Facts (Zacks)
11:23AM	Can Qualcomm's Snapdragon Ride Flex for Hyundai Work Wonders? (Zacks)
09:24AM	ADI Climbs 35.7% in a Year: Should You Buy, Sell or Hold the Stock? (Zacks)
Jan-08-26 09:36AM	What Makes NXP Semiconductors NV (NXPI) an Attractive Investment? (Insider Monkey)
Jan-07-26 04:59PM	How NXP Semiconductors Stock Gained 11.4% Last Month (Motley Fool)
11:21AM	Stocks Hover Near Record Highs on Mixed US Economic News (Barchart)
10:07AM	Stocks Supported by Lower Bond Yields (Barchart)
09:55AM	NXP Semiconductors (NXPI) Recently Broke Out Above the 20-Day Moving Average (Zacks)
Jan-06-26 04:34PM	S&P 500 and Dow Rally to Record Highs as Tech Stocks Surge (Barchart) +9.86%
01:35PM	The chip sector is headed for its first record in a month, led by some unsuspecting stocks (MarketWatch)
01:21PM	The surprising stocks powering the chip sector toward its first new high in a month (MarketWatch)
12:00PM	NXP Advances Edge AI Leadership with New eIQ Agentic AI Framework (GlobeNewswire)
11:00AM	NXP and GE HealthCare Accelerate AI Innovation in Acute Care (GlobeNewswire)
Jan-05-26 12:00PM	NXP's New S32N7 Unlocks the Full Potential of SDVs (GlobeNewswire)
10:00AM	Stocks Climb on AI Spending Optimism and Strength in Energy Producers (Barchart)
04:37AM	Earnings Preview: What to Expect From NXP Semiconductors Report (Barchart)
Jan-01-26 11:31PM	3 Volatile Stocks with Open Questions (StockStory)
Dec-29-25 06:22AM	Stocks Set to Open Lower as Investors Trim Risk at Year-End, Fed Minutes Awaited (Barchart)
Dec-28-25 11:41PM	3 Hyped Up Stocks We Approach with Caution (StockStory)
Dec-25-25 11:56AM	Analysts Confident in NXP Semiconductors (NXPI) Amid Improving Outlook on Diversified Analog Semiconductor Market (Insider Monkey)
Dec-24-25 02:23PM	Stocks End Mildly Higher as Bullish Sentiment Continues (Barchart)
Dec-23-25 06:15PM	NXP Semiconductors (NXPI) Stock Dips While Market Gains: Key Facts (Zacks)

NXP Semiconductors NV is a holding company which engages in the provision of semiconductor solutions. It operates through the following geographical segments: China, Netherlands, United States, Singapore, Germany, Japan, South Korea, Malaysia, and Other Countries. The company was founded on August 2, 2006, and is headquartered in Eindhoven, the Netherlands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hardy Andrew	Chief Sales Officer	Feb 04 '26	Option Exercise	0.00	823	0	7,755	Feb 05 06:14 AM
Wuamett Jennifer	EVP & General Counsel	Jan 02 '26	Sale	220.94	12,425	2,745,218	11,811	Jan 06 07:18 AM
JENNIFER B WUAMETT	Officer	Jan 02 '26	Proposed Sale	220.94	12,425	2,745,218		Jan 02 04:03 PM
Micallef Andrew	EVP, Chief Operations Officer	Dec 15 '25	Sale	230.78	1,000	230,780	10,942	Dec 17 04:16 PM
ANDREW J MICALLEF	Officer	Dec 15 '25	Proposed Sale	230.78	1,000	230,780		Dec 15 04:01 PM
Jensen Christopher L	EVP, Chief People Officer	Dec 03 '25	Sale	228.17	2,300	524,791	9,965	Dec 05 06:17 AM
Southern Julie	Chair	Dec 03 '25	Buy	225.48	225	50,733	11,937	Dec 05 06:14 AM
CHRISTOPHER JENSEN	Officer	Dec 03 '25	Proposed Sale	228.17	2,300	524,799		Dec 03 05:24 PM
Hardy Andrew	Chief Sales Officer	Apr 30 '25	Option Exercise	0.00	4,879	0	8,668	Dec 03 04:27 PM
Betz William	EVP & CFO	Nov 13 '25	Sale	201.93	7,299	1,473,887	1,520	Nov 14 04:10 PM
WILLIAM J BETZ	Officer	Nov 13 '25	Proposed Sale	201.93	7,299	1,473,899		Nov 13 04:04 PM
Micallef Andrew	EVP, Chief Operations Officer	Nov 07 '25	Option Exercise	0.00	1,453	0	10,074	Nov 12 07:24 AM
Hardy Andrew	Chief Sales Officer	Nov 07 '25	Option Exercise	0.00	807	0	3,672	Nov 12 07:24 AM
Sotomayor Rafael	CEO & President	Nov 07 '25	Option Exercise	0.00	1,614	0	8,594	Nov 12 07:24 AM
Betz William	EVP & CFO	Nov 07 '25	Option Exercise	0.00	1,614	0	5,611	Nov 12 07:24 AM
Jensen Christopher L	EVP, Chief People Officer	Nov 07 '25	Option Exercise	0.00	1,480	0	9,480	Nov 12 07:24 AM
Wuamett Jennifer	EVP & General Counsel	Nov 07 '25	Option Exercise	0.00	1,480	0	21,464	Nov 12 07:23 AM
Sotomayor Rafael	CEO & President	Nov 05 '25	Option Exercise	0.00	1,558	0	7,535	Nov 07 08:07 AM
Micallef Andrew	EVP, Chief Operations Officer	Nov 05 '25	Option Exercise	0.00	1,335	0	9,096	Nov 07 08:07 AM
Betz William	EVP & CFO	Nov 05 '25	Option Exercise	0.00	1,558	0	4,448	Nov 07 08:07 AM
Wuamett Jennifer	EVP & General Counsel	Nov 05 '25	Option Exercise	0.00	1,335	0	20,510	Nov 07 08:07 AM
Jensen Christopher L	EVP, Chief People Officer	Nov 05 '25	Option Exercise	0.00	1,335	0	8,499	Nov 07 08:07 AM
Hardy Andrew	Chief Sales Officer	Nov 05 '25	Option Exercise	0.00	742	0	3,241	Nov 07 08:07 AM
Wuamett Jennifer	EVP & General Counsel	Nov 04 '25	Sale	207.01	8,372	1,733,056	19,175	Nov 06 04:10 PM
JENNIFER B WUAMETT	Officer	Nov 04 '25	Proposed Sale	207.01	8,372	1,733,056		Nov 04 04:10 PM
Micallef Andrew	EVP, Chief Operations Officer	Nov 01 '25	Option Exercise	0.00	1,449	0	8,277	Nov 04 08:16 AM
Betz William	EVP & CFO	Nov 01 '25	Option Exercise	0.00	1,811	0	3,331	Nov 04 08:16 AM
Jensen Christopher L	EVP, Chief People Officer	Nov 01 '25	Option Exercise	0.00	1,582	0	7,755	Nov 04 08:15 AM
Sotomayor Rafael	CEO & President	Nov 01 '25	Option Exercise	0.00	1,582	0	6,540	Nov 04 08:15 AM
Hardy Andrew	Chief Sales Officer	Nov 01 '25	Option Exercise	0.00	715	0	2,861	Nov 04 08:15 AM
Wuamett Jennifer	EVP & General Counsel	Nov 01 '25	Option Exercise	0.00	1,582	0	28,170	Nov 04 08:15 AM
Micallef Andrew	EVP, Chief Operations Officer	Sep 15 '25	Sale	216.21	1,000	216,210	6,828	Sep 16 05:12 PM
ANDREW J MICALLEF	Officer	Sep 15 '25	Proposed Sale	216.21	1,000	216,210		Sep 15 04:51 PM
Sotomayor Rafael	President	Aug 12 '25	Sale	219.57	2,000	439,149	4,958	Aug 14 06:23 AM
RAFAEL SOTOMAYOR	Director	Aug 12 '25	Proposed Sale	219.57	2,000	439,149		Aug 12 06:02 PM
Betz William	EVP & CFO	Jul 28 '25	Sale	227.34	6,785	1,542,502	1,520	Jul 29 05:30 PM
WILLIAM J BETZ	Officer	Jul 28 '25	Proposed Sale	227.34	6,785	1,542,506		Jul 28 05:21 PM
Wuamett Jennifer	EVP & General Counsel	Jul 02 '25	Sale	230.00	9,132	2,100,360	27,088	Jul 03 06:19 PM
JENNIFER B WUAMETT	Officer	Jul 02 '25	Proposed Sale	230.00	9,132	2,100,360		Jul 02 04:37 PM
Micallef Andrew	EVP, Chief Operations Officer	Jun 16 '25	Sale	213.94	1,000	213,940	7,828	Jun 18 04:14 PM
ANDREW J MICALLEF	Officer	Jun 16 '25	Proposed Sale	213.94	1,000	213,940		Jun 16 05:14 PM
Foxx Anthony R	Director	May 29 '25	Option Exercise	0.00	822	0	3,293	Jun 02 04:30 PM
SUMME GREGORY L	Director	May 29 '25	Option Exercise	0.00	822	0	8,530	Jun 02 04:29 PM
Staiblin Jasmin	Director	May 29 '25	Option Exercise	0.00	822	0	6,916	Jun 02 04:29 PM
Sundstrom Karl-Henrik	Director	May 29 '25	Option Exercise	0.00	822	0	4,378	Jun 02 04:29 PM
GAVRIELOV MOSHE	Director	May 29 '25	Option Exercise	0.00	822	0	1,502	Jun 02 04:29 PM
Chunyuan Gu	Director	May 29 '25	Option Exercise	0.00	822	0	2,581	Jun 02 04:28 PM
CLAYTON ANNETTE K	Director	May 29 '25	Option Exercise	0.00	822	0	3,293	Jun 02 04:28 PM
Southern Julie	Chair	May 29 '25	Option Exercise	0.00	822	0	12,119	Jun 02 04:28 PM
Olving Lena	Director	May 29 '25	Option Exercise	0.00	822	0	4,372	Jun 02 04:28 PM
Micallef Andrew	EVP, Chief Operating Officer	Mar 17 '25	Sale	204.86	1,000	204,860	8,828	Mar 18 04:02 PM
ANDREW J MICALLEF	Officer	Mar 17 '25	Proposed Sale	204.86	1,000	204,860		Mar 17 04:18 PM

LGND

Ligand Pharmaceuticals, Inc

NXPI

NXP Semiconductors NV

Upgrade your FINVIZ experience